Syndax Pharmaceuticals Inc is a pioneering biopharmaceutical firm focused on crafting innovative therapies for cancer treatment. At the forefront of its development pipeline are revumenib, aimed at tackling acute leukemias and solid tumors, and axatilimab, designed for chronic graft versus host disease and idiopathic pulmonary fibrosis. Additionally, the company is advancing Entinostat, with strategic partnerships enhancing its global reach. Founded in 2005 and based in Waltham, Massachusetts, Syndax is committed to addressing unmet medical needs in oncology.
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share…
